French authorities open judicial inquiry into food poisoning of children
A judicial inquiry has been opened alongside a health investigation, into the severe food poisoning cases in northern France since 12 June. This comes after the death of a 12-year-old girl and reports of at least 19 children who fell ill.
The prosecutor's office in Saint-Quentin announced on Monday that a preliminary judicial inquiry for involuntary homicide had been opened last week, alongside a health investigation.
"This preliminary investigation was opened against unknown persons on charges of involuntary manslaughter, involuntary injury, endangering the lives of others and deception regarding goods presenting a danger to human life," according to a press release from the public prosecutor's office.
Authorities in the Aisne department announced that the number of victims had risen to 19 after another child had been admitted to hospital with symptoms of food poisoning.
French health chiefs identify E coli as cause of major food poisoning outbreak
Eight of these young patients developed hemolytic uremic syndrome (HUS), a serious complication characterised in particular by acute renal failure, one of whom, a 12-year-old girl, died on 16 June.
Currently, six children who contracted HUS are still receiving dialysis, while ten other children have been able to leave the hospital and return home, while receiving "continuous medical monitoring," the prefecture said in a statement.
Read more on RFI EnglishRead also:Frozen pizza blamed for deadly E coli infections sweeping FranceFrench brand recalls yoghurts contaminated with E coli bacteriaWoman dies in Bordeaux botulism outbreak linked to sardines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
2 hours ago
- Health Line
Oligodendroglioma
Oligodendroglioma is a rare tumor that develops in the brain with no known cause. It tends to have a higher survival rate compared to most other brain tumors, but early diagnosis and treatment are key. Oligodendroglioma belongs to a group of brain tumors called gliomas. Gliomas are primary tumors. This means they originated in the brain rather than spreading from elsewhere in the body. The National Brain Tumor Society reports that around 1.2% of all brain tumors are classified as an oligodendroglioma. They are typically divided into two types: grade 2 (slow growing) grade 3 (fast growing) Oligodendroglioma is more commonly diagnosed in adults, though young children can also be affected. Life expectancy and survival rate According to the American Cancer Society, the 5-year relative survival rate for people with an oligodendroglioma is as follows: 90% for those ages 22 to 44 years 82% for those ages 45 to 54 years 69% for those ages 55 to 64 years The relative survival rate suggests how long someone with a condition may live after receiving their diagnosis compared to someone without the condition of the same race, sex, and age over a specific time. This is different from overall survival rate, which is a percentage of people still alive for a specific time after receiving a diagnosis. It's most important to remember that these figures are estimates, and everyone is different. You can talk with your doctor about your specific condition. Several factors can affect your survival rate, including the grade of the tumor and how early it was diagnosed, as well as your overall health. Symptoms Oligodendroglioma can lead to a wide variety of symptoms. Seizure is the most common symptom — about 60% of people experience a seizure before receiving an oligodendroglioma diagnosis, according to the National Cancer Institute. Other symptoms include: headache cognitive changes weakness or numbness in the limbs issues with balance or movement However, the symptoms you experience can vary based on the size of the tumor and which part of your brain the tumor is growing in. What are the causes? There are no known causes of oligodendroglioma. Genetic changes are thought to play a role in the development of oligodendroglioma. Factors such as radiation exposure may also increase the risk of developing this type of tumor. Treatment options There are a number of treatment options available. You and your doctors will work together to decide what's the best course of action is in your case. Your medical team will base their decisions upon a number of factors, including: your overall health the grade and location of your tumor the final diagnosis given by a neurosurgeon Surgery Surgery is typically the first-line treatment for oligodendroglioma. The goal is to remove as much of the tumor as possible. Other treatment If the tumor cannot be completely removed with surgery, additional treatment may be used to avoid recurrence, such as: Radiation therapy: This involves the use of high energy rays. It's typically used after surgery to help kill any tiny fragments of the tumor that may remain. Chemotherapy: This treatment uses cytotoxic drugs to help kill cancer cells and can be used before and after radiotherapy. It's also useful for shrinking brain tumors, particularly those that cannot be surgically removed. Targeted therapy: This treatment can be used to slow tumor regrowth. Clinical trials: Your doctor may recommend enrolling in a clinical trial to test potential new treatment options. Antiseizure medication: If you experience seizures, these medications will likely be a part of your treatment plan. Outlook and recurrence The outlook for oligodendroglioma tumors depends on factors such as the tumor grade, the overall health of the person with the diagnosis, and how early the tumor was diagnosed. People who receive a diagnosis and begin treatment early have a higher chance of survival. Overall, those who have an oligodendroglioma tend to have a higher survival rate than most other brain tumors. Many treatment options are available, and oligodendroglioma appears to respond well to treatment. It's unusual to be able to completely remove the tumor, but it's possible to prolong the life of someone with an oligodendroglioma. Successful treatment plans often employ several methods. This reduces the chance that the tumor will recur. Like all other gliomas, oligodendroglioma has a very high rate of recurrence and often gradually increases in grade over time. Recurrent tumors are often treated with more aggressive forms of chemotherapy and radiation therapy.
Yahoo
4 hours ago
- Yahoo
Gene drive and mosquitoes: Turning a deadly foe into an ally
Malaria remains a daily threat across Africa. In 2023 alone, the continent accounted for 95% of the world's 597,000 malaria-related deaths. The most vulnerable are our children and pregnant women. Every minute, a child in Africa dies from this disease. But malaria doesn't just rob us of lives, it also drains our economies. Across Africa, the disease costs us an estimated $12 billion each year. In Uganda, my home country, we lose more than $500 million per decade. During peak seasons, malaria can cause up to half of all outpatient visits and nearly a fifth of hospital admissions. Worse still, the challenges are growing. Climate change, resistance to insecticides, and reduced effectiveness of antimalarial drugs are threatening the progress we've made. So, we're left with a difficult question: Must we accept malaria as an inevitable part of life? I don't believe we should. And as both a scientist and a mother, I believe we can do more. At Target Malaria, the nonprofit research consortium I work with, we're exploring a new frontier in the fight against malaria: gene drive technology. Here's how it works: We introduce a genetic trait into the Anopheles mosquito, one of the main carriers of the malaria parasite. This gene is passed down to offspring at a higher-than-normal rate, gradually reducing the population's ability to reproduce. Over time, the mosquito population declines — potentially enough to interrupt malaria transmission altogether. A large-scale modeling study across 13 West African countries showed that gene drive mosquitoes could reduce populations of malaria-transmitting species by 71% to 98%. When combined with existing tools like vaccines and new-generation mosquito nets, it could prevent up to 60% more clinical malaria cases. This technology is not designed to eradicate all mosquitoes — nor could it. Of more than 3,500 known mosquito species, only about 30 are a public health concern. Of those, just three are responsible for most malaria transmission in Africa. Our work is focused on this narrow target. Genetic approaches also offer some clear advantages for Africa's unique health landscape. They require less day-to-day management than current interventions, making them particularly suited for rural and hard-to-reach communities. And because they are species-specific, they offer a more environmentally targeted solution. But we are taking a cautious, transparent approach. We're still years away from releasing gene drive mosquitoes into the wild — and we won't take that step without the required regulatory approvals and the agreement of the communities involved. In the meantime, we are conducting rigorous ecological studies to ensure that reducing one mosquito species won't cause ripple effects in the environment. Early results of ecological studies conducted on the Anopheles mosquitoes in Ghana are promising. Animals, like birds and bats, that prey on these mosquitoes appear to have a varied diet and thus would be able to survive without them. We're also listening to community members, civil society groups, and environmental advocates have voiced concerns because science must serve people, not just data. Malaria isn't just a scientific challenge — it's personal. I have lost people I love to this disease. I have watched it strike hardest in communities that already face poverty, limited health access, and climate vulnerability. Science gives us the tools to change the future. Gene drive won't be a silver bullet. But as part of an integrated approach alongside existing tools and partnerships, it could help turn one of our oldest enemies into an unlikely ally. This isn't science fiction. It's science — African-led, community-centered, and driven by hope. And that's a future worth fighting for.
Yahoo
4 hours ago
- Yahoo
French authorities open judicial inquiry into food poisoning of children
A judicial inquiry has been opened alongside a health investigation, into the severe food poisoning cases in northern France since 12 June. This comes after the death of a 12-year-old girl and reports of at least 19 children who fell ill. The prosecutor's office in Saint-Quentin announced on Monday that a preliminary judicial inquiry for involuntary homicide had been opened last week, alongside a health investigation. "This preliminary investigation was opened against unknown persons on charges of involuntary manslaughter, involuntary injury, endangering the lives of others and deception regarding goods presenting a danger to human life," according to a press release from the public prosecutor's office. Authorities in the Aisne department announced that the number of victims had risen to 19 after another child had been admitted to hospital with symptoms of food poisoning. French health chiefs identify E coli as cause of major food poisoning outbreak Eight of these young patients developed hemolytic uremic syndrome (HUS), a serious complication characterised in particular by acute renal failure, one of whom, a 12-year-old girl, died on 16 June. Currently, six children who contracted HUS are still receiving dialysis, while ten other children have been able to leave the hospital and return home, while receiving "continuous medical monitoring," the prefecture said in a statement. Read more on RFI EnglishRead also:Frozen pizza blamed for deadly E coli infections sweeping FranceFrench brand recalls yoghurts contaminated with E coli bacteriaWoman dies in Bordeaux botulism outbreak linked to sardines
